Clinical Study

Bms Ca031-002- A Phase 1/2 First-In-Human Study Of Bms-986258 Alone And In Combination With Nivolumab In Advanced Malignant Tumors

Posted Date: Sep 7, 2020

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine whether BMS-986258 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors. The primary endpoint of this study is to determine the incidence of AEs, SAEs, AEs meeting protocol-defined DLT criteria, AEs leading to discontinuation, and death.


To Be Eligible: Must Have Confirmed Diagnosis Of Hcc Localized To The Liver And Not Amenable To Curative Treatment, Adequately Controlled Blood Pressure With Or Without Antihypertensive Medications, Not Currently A Candidate For Liver Transplantation, No Gastric Bleeding Within The Last 6 Months, No Significant Cardiovascular Impairment Within 12 Months, No Serious Nonhealing Wound, Ulcer, Or Bone Fracture


Advanced Malignant Tumors, Cancer, Phase 1

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.